| Composition | Acarbose 25mg |
|---|---|
| Dosage | TABLET |
| Packing Size | 20×10 |
| Packing | Alu-Alu |
Introduction
ACRICOP 25 is a premium-quality pharmaceutical formulation containing Acarbose 25mg, an oral alpha-glucosidase inhibitor widely used in the management of Type 2 Diabetes Mellitus (T2DM). Designed to effectively regulate postprandial (after-meal) blood glucose levels, ACRICOP 25 is an excellent option for patients seeking reliable glycemic control as part of a comprehensive diabetes management plan. Its mechanism of action is based on slowing down carbohydrate absorption in the intestines, helping to minimize sudden spikes in blood sugar after meals.
Active Ingredient: Acarbose – 25mg
Dosage Form: Tablet
Packing: Available in high-quality blister packs, ensuring product stability and convenience of use.
Acarbose, the active ingredient in ACRICOP 25, belongs to a class of medications called alpha-glucosidase inhibitors. It works by:
Inhibiting Alpha-Glucosidase Enzymes: Acarbose blocks enzymes in the small intestine responsible for breaking down complex carbohydrates into simple sugars.
Delaying Glucose Absorption: By slowing carbohydrate digestion, it helps maintain a gradual release of glucose into the bloodstream.
Controlling Postprandial Hyperglycemia: This delayed absorption prevents sudden spikes in blood sugar after meals, improving overall glycemic control.
Unlike other oral antidiabetic drugs, Acarbose does not stimulate insulin secretion, reducing the risk of hypoglycemia when used alone.
ACRICOP 25 is primarily indicated for:
Type 2 Diabetes Mellitus (T2DM):
Used as monotherapy or in combination with other oral antidiabetic agents (such as metformin or sulfonylureas).
Helps improve glycemic control, especially post-meal glucose levels.
Prevention of Type 2 Diabetes in Prediabetic Patients:
In patients with impaired glucose tolerance (IGT), Acarbose has been shown to delay or reduce the risk of progression to Type 2 diabetes.
Adjunct Therapy:
Works well alongside diet, exercise, and lifestyle modification for optimal diabetes management.
Effective Postprandial Control:
Acarbose specifically targets after-meal glucose spikes, making it a unique and effective option.
Non-Insulinotropic Action:
It does not increase insulin levels, reducing the risk of hypoglycemia when not combined with insulin or sulfonylureas.
Weight-Neutral Drug:
Unlike some other antidiabetic agents, Acarbose is generally weight-neutral, making it ideal for overweight or obese patients with diabetes.
Combination Therapy Potential:
ACRICOP 25 works well in combination with other oral hypoglycemic agents for patients requiring multi-drug regimens.
Recommended Dosage:
The usual starting dose is 25mg orally, three times daily, taken at the start of each main meal.
The dose can be gradually increased based on individual patient response and tolerance, typically up to 50mg or 100mg per meal.
Route: Oral
Important Note: Tablets should be chewed with the first bite of food or swallowed whole with a little water.
Drug Class: Alpha-Glucosidase Inhibitor
Onset of Action: Works locally in the intestine within hours of administration.
Metabolism: Primarily metabolized in the gastrointestinal tract by intestinal enzymes and gut bacteria.
Elimination: Excreted mostly in the feces.
Acarbose is generally well-tolerated. The most common side effects are gastrointestinal in nature due to its mechanism of action:
Flatulence (gas)
Abdominal discomfort
Diarrhea or soft stools
These effects usually diminish as the body adjusts to therapy or with adherence to dietary recommendations (low simple sugar intake).
Rare side effects:
Liver enzyme elevation (monitor liver function tests in long-term therapy).
Allergic skin reactions (rare).
Liver Function: Periodic liver enzyme tests are recommended during prolonged therapy.
Gastrointestinal Conditions: Not suitable for patients with chronic intestinal diseases, inflammatory bowel disease, or intestinal obstruction.
Renal Impairment: Use cautiously in patients with severe renal dysfunction (serum creatinine >2 mg/dL).
Hypoglycemia Management:
When combined with insulin or sulfonylureas, hypoglycemia may occur.
Treat hypoglycemia with pure glucose (dextrose), not sucrose, as Acarbose delays sucrose breakdown.
To maximize the benefits of ACRICOP 25, patients should:
Follow a balanced diabetic diet rich in fiber and low in refined carbohydrates.
Exercise regularly to improve insulin sensitivity.
Monitor blood glucose levels regularly, especially postprandial readings.
Adhere to prescribed medications and doctor visits.
Reduced Efficacy: Antacids, digestive enzyme preparations (amylase, pancreatin), and intestinal absorbents like charcoal can reduce Acarbose effectiveness.
Hypoglycemia Risk: Concurrent use with insulin, sulfonylureas, or metformin can increase the risk of hypoglycemia.
Warfarin: Monitor INR as Acarbose may have a mild effect on warfarin metabolism.
Targeted Postprandial Glucose Control: Ideal for patients struggling with blood sugar spikes after meals.
Clinically Proven: Backed by research demonstrating its effectiveness in managing diabetes and preventing progression in prediabetic patients.
Flexible Use: Works well alone or with other diabetes medications.
Weight Neutral: Perfect for overweight diabetic patients.
Quality Assurance: Manufactured under stringent quality standards, ensuring safety, efficacy, and consistency.
Store in a cool, dry place away from direct sunlight.
Keep tablets in their original blister packaging until use.
Keep out of reach of children.
ACRICOP 25 (Acarbose 25mg) is a trusted alpha-glucosidase inhibitor that helps patients with Type 2 Diabetes Mellitus achieve better glycemic control, particularly by reducing post-meal glucose spikes. It is a safe, effective, and well-tolerated medication that complements lifestyle modifications and other antidiabetic agents. Its weight-neutral profile and targeted mechanism of action make it a preferred choice for clinicians managing diabetes in patients of varying age groups.
Whether used as a standalone therapy or as part of a combination regimen, ACRICOP 25 provides consistent results and enhances long-term health outcomes for diabetic patients.
